Bayer consolidates US glyphosate business in new unit Ruveon

With the spin-off, Bayer says it aims to respond more quickly to competition from generic products. Bayer justified the move by saying that Ruveon would be able to act more agilely on its own and thus better address the specific competitive dynamics of a market shaped by generic products. The product and sales teams previously responsible for the US glyphosate business will transfer entirely to Ruveon.

Wave of lawsuits over Roundup

The background to the reorganization is the wave of lawsuits against Bayer in the US that has been ongoing for years. The company faces a wave of lawsuits in the US over alleged cancer risks from glyphosate-containing herbicides such as Roundup. Bayer rejects the allegations and denies that Roundup poses a cancer risk.

Just last week, the Supreme Court of the United States ruled in favor of the company in a case significant for Bayer. The justices found that Bayer cannot be sued for failing to place cancer warnings on the packaging of the herbicide. The company pointed out that the responsible US environmental agency, the EPA, mandates uniform labeling and that individual states cannot enforce deviating requirements.

Supreme Court strengthens Bayer

The court's reasoning rests on the fact that uniform labeling in the US is mandated by the Environmental Protection Agency (EPA), meaning that individual states cannot impose differing requirements. As a result, the expectation is that numerous Roundup lawsuits will lose their basis. Thousands of cases could be rendered moot by the ruling.

In parallel with the legal victory, Bayer had already reached a multibillion-dollar settlement in February. At that time, the company agreed with plaintiffs on a settlement of 7.25 billion US dollars, equivalent to approximately 6.4 billion euros, to resolve the class-action lawsuits. This settlement has already received preliminary approval; the hearing on final approval is scheduled for August 19.

Billions settlement in the background

With the spin-off into the new unit Ruveon, the company says it is creating clearer responsibilities for the contested US market. Ruveon is to focus on all aspects of the US glyphosate business – from pricing to production and logistics. This is also accompanied by stronger local roots: the company is headquartered in St. Louis, Missouri.

The news was received positively in the financial markets. On the morning of the announcement, the Bayer share rose by around two percent on the off-exchange trading platform Tradegate. The company, which also operates agrochemical and pharmaceutical businesses, sees itself strategically better positioned against competition from generics through the restructuring.

The spin-off explicitly does not mean a separation from the Bayer Group. Ruveon will remain part of the Bayer Group, it was said from Leverkusen. The structure is intended to give management greater entrepreneurial flexibility without separating legal and financial responsibility from the parent company.

Market reaction and outlook

The wave of lawsuits against Bayer has for years been a significant burden on the company. Bayer faces a wave of lawsuits in the US over alleged cancer risks from glyphosate-containing herbicides such as Roundup. In addition to the settlement now reached, further individual cases remain pending, the outcome of which is still open.

The Leverkusen-based company responded to the pressure with a dual strategy of legal and organizational restructuring. While the Supreme Court ruling could devalue many lawsuits, Ruveon is to operate the glyphosate business in the US independently going forward.

Bayer says it is convinced that the new structure represents the right answer to the challenges in the US market. Ruveon will be responsible from St. Louis for all aspects of the glyphosate business, from pricing to production, it added. This, the company said, will allow the new unit to operate closer to the customer and to the competition.

Strategy behind the move

The announcement from Leverkusen came on a day of broader reporting. This news was broadcast on 02.07.2026 on the Deutschlandfunk program. Industry observers interpret the move as a signal that, despite ongoing legal risks, Bayer is sticking with its glyphosate business and intends to strengthen it through consolidation.

The Leverkusen-based company, an international agrochemical and pharmaceutical group, faces particular difficulties in the US precisely because of the Roundup legacy of the acquired Monsanto. With the creation of Ruveon, Bayer aims to bundle this legacy operationally without giving up the brand and the connection to the parent company.

At the same time, the legal dispute does not stand still: even though the Supreme Court ruling takes the ground from under many lawsuits, it remains to be seen how individual cases will develop and what impact the final approval of the class-action settlement in August will have.